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mechanical measurements on single scaffold struts were also per-
formed to evaluate the mechanical response of individual struts.
RESULTS 3.0mm and 3.5mm scaffold sizes could be post-expanded
up to 1 mm above their nominal diameters without any strut fracture
when deployed without an external constraining model. Over-
expansion with balloon sizes 1.5 mm above the scaffold nominal
diameter produced strut fractures in both sizes: 3.0mm scaffolds
oversized with NC balloon resulted in more strut fracture sites (on
average 12.7  3.9) as compared to oversized 3.5mm scaffolds
(1.31.2). Importantly, when overexpansion of a series of 3.0mm and
3.5mm scaffolds was repeated using a constrained silicon lesion
model, only post-expansion with NC balloon 0.5mm larger than
nominal size could be performed without causing strut fractures. The
point force single strut compression analysis shows that post-dilated
rings with fractures had the lowest local focal strength; overexpanded
ring segments without fractures had also a lower focal mechanical
strength than normal segments (expanded at nominal pressure).
Maximum point force measured for fractured, overexpanded without
fracture and normal ring were respectively: 0.17, 0.29 and 0.44 N for
BVS 3.0mm size (p < 0.01); and 0.19, 0.30 and 0.33 N for BVS 3.5mm
size (p < 0.01).
CONCLUSIONS In our experiments, only overexpansion with 0.5mm
NC balloon was feasible for BVS deployed inside an arterial lesion
model. Over-expansion of the BVS scaffold beyond recommended
post-dilation limits can lead to strut disconnections and local loss of
mechanical support.
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BACKGROUND The natural history of incomplete scaffold implanta-
tion (ISA) after BVS implantation in thrombotic lesions of STEMI has
not been elucidated. We evaluated the incidence of persistent,
resolved and late ISA after BVS implantation in STEMI.
METHODS The BVS-STEMI–ﬁrst is a cohort study that enrolled 39
consecutive patients previously admitted with STEMI and treated
with BVS at the index procedure that consented to undergo invasive
follow-up by angiography and OCT at 6 months. Twenty of thirty nine
patients had also undergone OCT post implantation. In this subgroup,
serial analysis of OCT parameters was performed. Moreover, all mal-
apposed struts were identiﬁed on a frame-level basis (0.2mm interval)
for both pullbacks, and plotted in spread-out maps. The presence of
persistent, resolved, and late ISA was then estimated on a scaffold
level, by visual assessment of the maps and inspection of synchro-
nized pullbacks. Persistent ISA was deﬁned as presence of malap-
posed struts both at baseline and follow-up, resolved as malapposed
struts at baseline that were apposed at follow-up, while late as new
occurrence of malapposed struts at follow-up.
RESULTS Mean and minimal lumen area were reduced at follow-up
(p<0.001). There was no signiﬁcant difference for proximal or distal
reference lumen area, or for scaffold area. The number of malapposed
struts was non-signiﬁcantly reduced from baseline to follow-up (1.4%
vs.0.8%, p¼0.16). Malapposition distance increased from baseline to
follow-up (p<0.001), however there was no signiﬁcant difference in
the mean ISA area between the two intervals (p¼0.48). Spread-out
maps illustrating strut apposition post-implantation and at follow-up
are presented in the Figure. There were 3 patients (15%) with persis-
tent ISA, 11 patients (55%) with resolved ISA, and 6 patients (30%)
with late ISA.Post-implantation Follow-up p-valueMean Lumen
area(mm2)7.541.72 6.771.98 <0.001Minimal Lumen
area(mm2)5.811.49 4.891.92 <0.001Proximal Reference
area(mm2)7.302.08 6.692.52 0.10Distal Reference
area(mm2)6.413.22 7.213.67 0.29Mean Scaffold/Stent
area(mm2)8.011.78 8.271.98 0.17Min Scaffold/Stent
area(mm2)6.581.89 6.481.97 0.66Mean ISA area(mm2) 0 [0-0.027] 0 [0-0.034] 0.48Scaffold/stent-level
ISA(>5%) n(%)3(15.0) 1(5.0) 0.33Strut-level analysisStruts analyzed 4521 5227Malapposed struts 65 (1.44) 43 (0.82) 0.16Malapposition
distance(mm)210[130-400] 818[518-1238] <0.001CONCLUSIONS In the follow-up of BVS in STEMI, the majority of
cases with acute ISA are resolved. However, a fraction might remain
malapposed, while the incidence of late ISA is not negligible. Further
studies are warranted to evaluate the prognostic signiﬁcance of these
ﬁndings.
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BACKGROUND The ﬁrst commercially available bioresorbable scaf-
fold (BRS) Absorb has strut thickness of 150 microns, signiﬁcantly
more than contemporary drug-eluting stents. As such, it has potential
for lower deliverability and for higher thrombogenicity. Therefore,
decreasing the BRS strut thickness with no adverse effect on its
biomechanics appears desirable. In this study, we aimed to evaluate
the biological efﬁcacy of a novel sirolimus-eluting BRS (Amaranth
